|
KMID : 0378019990420050028
|
|
New Medical Journal
1999 Volume.42 No. 5 p.28 ~ p.33
|
|
|
The Antitussive and Mucolytic Effect of Erdosteine(Erdos ) in the Acute and Chronic Bronchitis
|
|
1박경옥/1Kyung Ok Park
1임성철/2윤명하/1황준화/1박창민/1고경행/1임명수/1박형관/1김영철/1Sung Chul Lim/2Myung Ha Yoon/1Jun Hwa Hwang/1Chang Min Park/1Kyung Haeng Ko/1Myung Su Lim/1Hyeong Kwan Park/1Young Chul Kim
|
|
|
Abstract
|
|
|
-Abstract-
Background : Erdosteine is a novel mucolytic agent endowed with mucomodulator and
antioxidant properties in vitro and in vivo. Also, previous study reported that it is able
to favor the penetration of antibiotics into bronchial secretion. We attempted to
investigate the therapeutic efficacy and tolerance of erdosteine in patients with acute and
chronic bronchitis
Method : Erdosteine(Erdos ) 600 ㎎/day was administrated for 7days in
26 patients with acute and chronic bronchitis. Clinical efficacy was determined using the
volume of sputum during 4 hours after awakening, sputum viscosity, sputum appearance,
severity of cough and difficulty to expectoration. And also, we evaluated clinical adverse
events and effects on laboratory indices.
Results :
1. The volume of sputum was significantly reduced from 9.7±8.2㎖ to 5.0± 4.2㎖ with
erdosteine(Erdos ) treatment(p<0.05).
2. The sputum viscosity was significantly attenuated from the scores of 1.5±0.6 to 1.1
±0.5 with Erdosteine treatment(p<0.05)
3. Sputum appearance was remarkablely improved from the scores of 1.7±0.7 to 1.1±
0.7(p< 0.05)
4. The severity of cough was significantly reduced from the scores of 1.7±0.9 to 1.0
±0.8(p< 0.05).
5. There were no considerable side effects to stop administration of drug.
6. The overall clinical efficacy rate for Erdosteine was 84.6% in patients wilt acute
and chronic bronchitis.
Conclusion : A newly developed mucolytic agent, erdosteine, has proven effective and
safe in the treatment of lower respiratory tract infection.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|